Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy

摘要

Hepatitis B virus(HBV)reactivation can lead to severe acute hepatic failure and death in patients with HBV infection.HBV reactivation(HBVr)most commonly develops in patients undergoing cancer chemotherapy,especially B cell-depleting agent therapy such as rituximab and ofatumumab for hematological or solid organ malignancies and that receiving hematopoietic stem cell transplantation without antiviral prophylaxis.In addition,the potential consequences of HBVr is particularly a concern when patients are exposed to either immunosuppressive or biologic therapies for the management of rheumatologic diseases,inammatory bowel disease and dermatologic diseases.Thus,screening with HBV serological markers and prophylactic or pre-emptive antiviral treatment with nucleos(t)ide analogues should be considered in these patients to diminish the risk of HBVr.This review discusses the clinical manifestation,prognosis and management of HBVr,risk stratifications of cancer chemotherapy and immunosuppressive therapy and international guideline recommendations for the prevention of HBVr in patients with HBV infection and resolved hepatitis B.